Effectiveness, safety, and impact on quality of life of eribulin-based therapy in heavily pretreated patients with metastatic breast cancer: A real-world analysis.

Published in: Cancer medicine (2023)

The present study suggests that eribulin-based therapy is an effective treatment option and well tolerated for heavily pre-treated patients with MBC. Eribulin combination therapy might improve PFS and HRQoL compared with eribulin monotherapy.

Keyphrases

metastatic breast cancer
combination therapy
randomized controlled trial
systematic review
stem cells
open label
cell therapy
phase iii